Shuttle Pharmaceuticals, Inc.
Annotated prostate cancer and normal epithelial cell lines from African-American patients, established using conditional reprogramming technology
- Sector
- Biotech
- Headquarters
- ROCKVILLE, MD
- Founded
- 2012
- Latest Form D
- $120K, Sep 2016
- Total capital
- $7.1M
- Federal grants
- $1.5M
- 1 award
- Rank in peer group#5 of 16
- Private capital raised
- $120K
- 1 Form D · last Sep 2016
- 121 months since last filing
- Federal contracts
- $5.5M
- 5 awards · Health and Human S
- Rank in Biotech#76 of 4373
- Granted patents
- 8
- 8 pending · first 2020
- Rank in peer group#3 of 16
Capital timeline
Latest events
- Federal contractHealth and Human S · Topic 345: Predictive Biomarkers Of Prostate Cancer Patient Sensitivity For Radiation Late Effects$1.9M
- Federal contractHealth and Human S · Igf::ot::igf Topic 352: Cell-based Models For Prostate Cancer Health Disparity Research- Moonshot Project (phase II)$1.5M
- Private capital raisedForm D · SEC · 1st filing$120K
- Federal contractHealth and Human S · Igf::ot::igf Predictive Biomarkers Of Prostate Cancer Patient Sensitivity For Radiation Late Effects$300K
- Federal contractHealth and Human S · Igf::ot::igf SBIR Phase I Topic 352 Cell-based Models For Prostate Cancer Health Disparity Research$225K
- Federal contractHealth and Human S · Igf::ot::igf R&d- Medical: Biomedical (basic Research)$1.6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Federal first
24months
from Shuttle Pharmaceuticals, Inc.’s first federal award to its first private round.
- First federal award · Sep 2014
- Health and Human S · $1.6M
- First Form D · Sep 2016
- $120K · 1st Form D
- Awards before first raise
- 3 awards
An association in public records, not a cause or a prediction.
Standing among 16 peers
Line = medianBiotech · Material
- Federal grants#5 · top 31%
- Granted patents#3 · top 19%
- Linked publications#1 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Anthony DritschiloExecutive Officer, DirectorNamed in SEC Form D filings
- Gene JungExecutive OfficerNamed in SEC Form D filings
- Michael StarkweatherExecutive OfficerNamed in SEC Form D filings
- Milton BrownExecutive Officer, DirectorNamed in SEC Form D filings
- Mira JungExecutive Officer, DirectorNamed in SEC Form D filings
- Peter DritschiloExecutive OfficerNamed in SEC Form D filings
Show all 7 people
- Theodore PhillipsExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 8 granted of 16- PendingMethods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With RadiationUSPTOApplication 19236725
- GrantedMethods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorlylase Inhibitors In Combination With RadiationUSPTOUS 12,357,650
- GrantedSelective Histone Deacetylase Inhibitors For The Treatment Of Human DiseaseUSPTOUS 12,077,515
Show all 16 patent records
- Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With RadiationOct 2, 2025 · Application 19236725Pending
- Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorlylase Inhibitors In Combination With RadiationJul 15, 2025 · US 12,357,650Granted
- Selective Histone Deacetylase Inhibitors For The Treatment Of Human DiseaseSep 3, 2024 · US 12,077,515Granted
- Selective Histone Deacetylase Inhibitors For The Treatment Of Human DiseaseMay 30, 2024 · Application 18154153Pending
- Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With RadiationSep 28, 2023 · Application 18194648Pending
- Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With RadiationMay 23, 2023 · US 11,654,157Granted
- Selective Histone Deacetylase Inhibitors For The Treatment Of Human DiseaseFeb 21, 2023 · US 11,584,733Granted
- Selective Histone Deacetylase Inhibitors For The Treatment Of Human DiseaseAug 9, 2022 · US 11,407,723Granted
- Dual Function Molecules For Histone Deacetylase Inhibition And Ataxia Telangiectasia Mutated Activation And Methods Of Use ThereofFeb 24, 2022 · Application 17484876Pending
- Selective Histone Deacetylase Inhibitors For The Treatment Of Human DiseaseJun 15, 2021 · US 11,034,667Granted
- Dual Function Molecules For Histone Deacetylase Inhibition And Ataxia Telangiectasia Mutated Activation And Methods Of Use ThereofOct 8, 2020 · Application 16910315Pending
- Dual Function Molecules For Histone Deacetylase Inhibition And Ataxia Telangiectasia Mutated Activation And Methods Of Use ThereofAug 18, 2020 · US 10,745,352Granted
- Dual Function Molecules For Histone Deacetylase Inhibition And Ataxia Telangiectasia Mutated Activation And Methods Of Use ThereofAug 4, 2020 · US 10,730,834Granted
- Selective Histone Deacetylase Inhibitors For The Treatment Of Human DiseaseApplication PCTUS2019012770Pending
- Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With RadiationApplication PCTUS2018012914Pending
- Selective Histone Deacetylase Inhibitors For The Treatment Of Human DiseaseApplication PCTUS2018012971Pending
Recent research by its founders
- Abstract 6607: HDAC6 inhibition modulates macrophage function in the post-radiation therapy tumor microenvironment.20260 cites
- Abstract 2148: HDAC6 inhibitors modulate macrophage functional activity in the post-radiotherapy tumor microenvironment20250 cites
- Supplementary Figure S1 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers20250 cites
Related companies, and why
- PAI LIFE SCIENCES INCSimilar federal contract value in Biotech · $5.8M in contracts
- 60 DEGREES PHARMACEUTICALS, INC.Similar federal contract value in Biotech · $5.8M in contracts
- FABRICO TECHNOLOGY, INC.Similar federal contract value in Biotech · $5.6M in contracts
- Inhalon Biopharma, Inc.Similar federal contract value in Biotech · $5.4M in contracts
- CELL MICROSYSTEMS INCSimilar federal contract value in Biotech · $5.1M in contracts
- PLATELET BIOGENESIS, INCSimilar federal contract value in Biotech · $5M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .